Name:
Radiotheraphy in....pdf
Size:
532.0Kb
Format:
PDF
Description:
Found with Open Access Button
Affiliation
The Christie NHS Foundation Trust, Manchester, United Kingdom. Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Manchester Biomedical Research Centre, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
PURPOSE: To review available and emerging evidence of radiotherapy for symptom management and disease control in metastatic bladder cancer. METHODS: A literature search and subsequent cross-referencing were carried out for articles in the PubMed and Scopus databases using terms 'radiotherapy' OR 'palliative radiation therapy' with 'metastatic bladder cancer' OR 'advanced bladder cancer' between 1990 and 2023, excluding articles with no English translation. RESULTS: Palliative radiotherapy is an effective and accessible treatment for the alleviation of haematuria and pain due to the primary and metastatic disease. With growing recognition of oligometastatic disease state at diagnosis, response, or progression, radiotherapy can consolidate response by ablating residual or resistant lesions. Experience with other primary cancers supports positive impact of radiotherapy on disease control, quality of life, and survival in oligometastatic stage, without significant adverse effects. Alongside immune checkpoint inhibitors, fibroblast growth receptor inhibitors, and antibody-drug conjugates, the immunomodulatory potential of radiotherapy is being explored in combination with these systemic therapies for metastatic bladder cancer. CONCLUSION: Radiotherapy is an effective, safe, and accessible treatment modality for palliation as well as disease control in various clinical settings of metastatic bladder cancer. Its role in oligometastatic stage in combination with systemic therapy is expected to expand with emerging evidence.Citation
Ashley S, Choudhury A, Hoskin P, Song Y, Maitre P. Radiotherapy in metastatic bladder cancer. World J Urol. 2024 Jan 20;42(1):47. PubMed PMID: 38244091. Pubmed Central PMCID: 10799782.Journal
World Journal of UrologyDOI
10.1007/s00345-023-04744-xPubMed ID
38244091Additional Links
https://dx.doi.org/10.1007/s00345-023-04744-xType
ReviewLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00345-023-04744-x
Scopus Count
Collections
Related articles
- Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?
- Authors: Augugliaro M, Marvaso G, Ciardo D, Zerini D, Riva G, Rondi E, Vigorito S, Comi S, De Cobelli O, Orecchia R, Jereczek-Fossa BA
- Issue date: 2019 Jan 15
- [Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases].
- Authors: Rebhan K, Gust KM
- Issue date: 2021 Dec
- Palliative radiation therapy of symptomatic recurrent bladder cancer.
- Authors: Yi SK, Yoder M, Zaner K, Hirsch AE
- Issue date: 2007 Mar
- The role of radiation therapy for de novo metastatic bladder and renal cancers.
- Authors: Sargos P, Le Guevelou J, Khalifa J, Albiges L, Azria D, de Crevoisier R, Supiot S, Créhange G, Roubaud G, Chapet O, Pasquier D, Blanchard P, Latorzeff I
- Issue date: 2024 Feb
- Is there a role for metastasis-directed therapy in bladder cancer?
- Authors: Abufaraj M, Al Karmi J, Bdeir A
- Issue date: 2024 Jul 1